The majority of cases of pancreatic cancer is diagnoses in locally advanced or metastatic clinical stage. Therapeutic approach to locally advanced and metastasising disease is different.
The future of targeted systemic treament is in identification of new structures to target, which have a leading role in transferring signals for proliferation of cancer cells and influence their metastatic potential.